Journal
IMMUNOBIOLOGY
Volume 228, Issue 3, Pages -Publisher
ELSEVIER GMBH
DOI: 10.1016/j.imbio.2023.152393
Keywords
-
Categories
Ask authors/readers for more resources
The SARS-CoV-2 virus, responsible for COVID-19, emerged in China in 2019 and rapidly spread worldwide, causing over 7 million deaths, with 2 million occurring before the introduction of the first vaccine. This review focuses on the relationship between complement and COVID-19 disease, highlighting the role of complement dysregulation in disease pathology. The potential therapeutic effects of complement-directed agents have been evaluated in small patient cohorts, but larger clinical trials are needed to validate these findings.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus was identified in China in 2019 as the causative agent of COVID-19, and quickly spread throughout the world, causing over 7 million deaths, of which 2 million occurred prior to the introduction of the first vaccine. In the following discussion, while recognising that complement is just one of many players in COVID-19, we focus on the relationship between complement and COVID-19 disease, with limited digression into directly-related areas such as the relationship between complement, kinin release, and coagulation. Prior to the 2019 COVID-19 outbreak, an important role for complement in coronavirus diseases had been established. Subsequently, multiple investigations of patients with COVID-19 confirmed that complement dysregulation is likely to be a major driver of disease pathology, in some, if not all, patients. These data fuelled evaluation of many complement-directed therapeutic agents in small patient cohorts, with claims of significant beneficial effect. As yet, these early results have not been reflected in larger clinical trials, posing questions such as who to treat, appropriate time to treat, duration of treatment, and optimal target for treatment. While significant control of the pandemic has been achieved through a global scientific and medical effort to comprehend the etiology of the disease, through extensive SARS-CoV-2 testing and quarantine measures, through vaccine development, and through improved therapy, possibly aided by attenuation of the dominant strains, it is not yet over. In this review, we summarise complement-relevant literature, emphasise its main conclusions, and formulate a hypothesis for complement involvement in COVID-19. Based on this we make suggestions as to how any future outbreak might be better managed in order to minimise impact on patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available